* agilon health inc AGL.N AGL is expected to show a rise
in
quarterly revenue when it reports results on February 27 for
the period ending December 31 2023
* The Austin Texas-based company is expected to report a
47.7% increase in revenue to $1.019 billion from $689.77 million
a year ago, according to the mean estimate from 15 analysts,
based on LSEG data.The company's guidance on November 2 2023,
for the period ended December 31, was for revenue between $1.05
billion and $1.06 billion.
* LSEG's mean analyst estimate for agilon health inc is for
a
loss of 28 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for agilon
health inc
is $11.00, above its last closing price of $6.27.
The company's guidance on November 2 2023 for the period ended
December 31 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between 1.05 billion and -24
million (USD).
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.07 -0.06 -0.08 Missed -40.5
Jun. 30 2023 -0.03 -0.03 -0.04 Missed -57.5
Mar. 31 2023 0.02 0.02 0.04 Beat 83.3
Dec. 31 2022 -0.07 -0.09 -0.14 Missed -62.8
Sep. -0.06 -0.05 -0.07 Missed -40
30 2022
Jun. 30 2022 -0.02 -0.02 -0.05 Missed -177.8
Mar. 31 2022 0.00 0.00 0.00 Met -100
Dec. 31 2021 -0.14 -0.11 -0.14 Missed -27.3
This summary was machine generated February 24 at 01:40 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)